標(biāo)題: Titlebook: Bone Drugs in Pediatrics; Efficacy and Challen Gordon L. Klein Book 2014 Springer Science+Business Media New York 2014 Anti-resorptive.Bisp [打印本頁] 作者: Holter-monitor 時間: 2025-3-21 16:26
書目名稱Bone Drugs in Pediatrics影響因子(影響力)
書目名稱Bone Drugs in Pediatrics影響因子(影響力)學(xué)科排名
書目名稱Bone Drugs in Pediatrics網(wǎng)絡(luò)公開度
書目名稱Bone Drugs in Pediatrics網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Bone Drugs in Pediatrics被引頻次
書目名稱Bone Drugs in Pediatrics被引頻次學(xué)科排名
書目名稱Bone Drugs in Pediatrics年度引用
書目名稱Bone Drugs in Pediatrics年度引用學(xué)科排名
書目名稱Bone Drugs in Pediatrics讀者反饋
書目名稱Bone Drugs in Pediatrics讀者反饋學(xué)科排名
作者: 懦夫 時間: 2025-3-21 22:54
Drug Development for Pediatric Diseases with Bone Loss,. We will provide the rationale for developing new anabolic drugs for treatment of bone loss in children. Three different approaches for drug discovery will be described, and new development of bone biology related to drug discovery target will be discussed in detail. Finally, we will talk about dru作者: 人類 時間: 2025-3-22 02:24 作者: 樹木心 時間: 2025-3-22 05:24
ing these drugs in the pediatric population.Highlights the p.Bone Drugs in Pediatrics. brings together in one place the evidence for the use of certain drugs in the treatment and prevention of bone loss in children, as well as the reservations still present in the pediatric community regarding their作者: indifferent 時間: 2025-3-22 10:22
https://doi.org/10.1007/978-3-662-12301-0thyroid hormone-related peptide, and their analogs. We also consider new molecules that are currently under development or of interest, including cathepsin K inhibitors, antisclerostin antibody, and nitric oxide.作者: FANG 時間: 2025-3-22 15:57 作者: urethritis 時間: 2025-3-22 17:04 作者: 引起 時間: 2025-3-22 22:36 作者: Vo2-Max 時間: 2025-3-23 02:00
Growth Hormone and Bone,. To improve linear growth and bone mineral metabolism, some recent studies have challenged GH treatment in patients with metabolic bone diseases, in addition to approved diseases. In this chapter, we describe the physiology of GH action, efficacy, and trials of GH treatment. The especially on bone mineral metabolism.作者: breadth 時間: 2025-3-23 06:09
Growth Hormone and Oxandrolone in Burned Children,g post-burn bone health outcomes. The systemic action of these anabolic agents beyond the bone metabolic system has also been explored in the clinical trials described. However, only bone-related markers are discussed in detail in this chapter.作者: 左右連貫 時間: 2025-3-23 11:27
Introduction,revent or treat pediatric bone loss. Even though no drugs have current approval for this purpose from the United States Food and Drug Administration (FDA), these chapters contain evidence of both safety and efficacy of antiresorptive and anabolic medications that have been used off-label in a variety of pediatric conditions.作者: 呼吸 時間: 2025-3-23 17:13
Developmental Pharmacokinetics: Drug Disposition Relative to Age,ge-appropriate dose for a drug is dependent on its pharmacokinetic profile which is markedly influenced by the normal developmental changes that occur in body water compartments and cellular and organ function. This chapter reviews the influence of patient age on drug pharmacokinetics in pediatrics.作者: mediocrity 時間: 2025-3-23 20:33 作者: Deadpan 時間: 2025-3-24 00:23
Use of Bisphosphonates in Genetic Diseases Other than Osteogenesis Imperfecta,to increase bone mass, reduce the risk of fractures, alleviate bone pain, and even, in some measure, hinder the formation of heterotopic bone. Only for the more common diseases, like Duchenne muscular dystrophy and cystic fibrosis, there are sufficient data to recommend the prudent use of BPs as a standard treatment of bone complications.作者: 圣人 時間: 2025-3-24 03:36
https://doi.org/10.1007/978-3-662-12290-7This chapter highlights the underlying physiological basis for these difficulties and describes the modalities used for monitoring the efficacy and safety of skeletal pharmacology in paediatric patients.作者: Gleason-score 時間: 2025-3-24 08:51
Astronomy and Astrophysics Abstractsvent the acute post-burn bone loss but also permit continued new bone mass accretion with time. The lack of side effects suggests that this drug can be used both safely and effectively in pediatric burn patients to prevent bone loss and the manner of its successful use may have applications to other pediatric conditions, which will be discussed.作者: Heterodoxy 時間: 2025-3-24 13:26 作者: 漂浮 時間: 2025-3-24 16:05
Paediatric Bone Physiology and Monitoring the Safety and Efficacy of Bone Drugs in Children,This chapter highlights the underlying physiological basis for these difficulties and describes the modalities used for monitoring the efficacy and safety of skeletal pharmacology in paediatric patients.作者: 急性 時間: 2025-3-24 20:51
Bisphosphonates in Pediatric Burn Injury,vent the acute post-burn bone loss but also permit continued new bone mass accretion with time. The lack of side effects suggests that this drug can be used both safely and effectively in pediatric burn patients to prevent bone loss and the manner of its successful use may have applications to other pediatric conditions, which will be discussed.作者: 合并 時間: 2025-3-25 03:03
Pediatric Bone Drugs: Calcium and Vitamin D,he sources and metabolism of calcium and vitamin D, the mechanism of their effect on bone, the significant pediatric studies that have shaped our understanding of this topic, and current recommendations guiding our use of calcium and vitamin D as pediatric bone drugs.作者: IOTA 時間: 2025-3-25 05:28 作者: 上腭 時間: 2025-3-25 11:18
Book 2014dren, as well as the reservations still present in the pediatric community regarding their use. Beginning with a discussion of developmental pharmacokinetics and drug development for pediatric diseases where bone loss occurs, such as osteogenesis imperfecta, the physiology of pediatric bone and how 作者: 容易生皺紋 時間: 2025-3-25 13:41
Siegfried B?hme,Walter Fricke,Gert Zechrevent or treat pediatric bone loss. Even though no drugs have current approval for this purpose from the United States Food and Drug Administration (FDA), these chapters contain evidence of both safety and efficacy of antiresorptive and anabolic medications that have been used off-label in a variety of pediatric conditions.作者: 遠(yuǎn)足 時間: 2025-3-25 19:45 作者: Misnomer 時間: 2025-3-25 23:15
Periodicals, Proceedings, Books, Activities,shown to decrease bone pain, enhance well-being and improve mobility and muscle strength, in addition to reducing the incidence of fractures. This chapter summarises the historical use, safety and efficacy of bisphosphonate therapy in children and adolescents with OI.作者: 多余 時間: 2025-3-26 02:31 作者: 圓桶 時間: 2025-3-26 07:24
Introduction,hild suffers from a genetic condition in which bone loss is flagrant the process of bone loss is often asymptomatic and if it occurs consequent to an underlying condition it does not attract medical attention. Therefore, this book undertakes to call to the reader’s attention the drugs available to p作者: Hallowed 時間: 2025-3-26 12:27
Developmental Pharmacokinetics: Drug Disposition Relative to Age,’s systemic circulation, distribute to its site of action, and bind to target receptors for a sufficient time period to realize these effects. A drug’s sojourn in the body, i.e., absorption, distribution, metabolism, and elimination, is described by the drug’s pharmacokinetic profile. The optimal, a作者: Sputum 時間: 2025-3-26 15:16 作者: 斷言 時間: 2025-3-26 18:30 作者: fringe 時間: 2025-3-26 20:59 作者: 乏味 時間: 2025-3-27 03:02 作者: 蛤肉 時間: 2025-3-27 06:37
Bisphosphonates in Pediatric Burn Injury,, as well as a consequent period of relative immobilization. It is likely that both the systemic inflammatory response through the production of cytokines and the stress response, through the production of endogenous glucocorticoids, stimulate acute bone loss by means of excess bone resorption follo作者: 進入 時間: 2025-3-27 12:01
Growth Hormone and Bone,th. GH treatment for its effect of growth in patients with many types of disorders of short stature has been expanding. In childhood, longitudinal bones become thick at the same time as long axis elongation, and bone quantity and bone mineral density (BMD) are elevated continuously until the adolesc作者: corn732 時間: 2025-3-27 15:40 作者: demote 時間: 2025-3-27 19:14
Pediatric Bone Drugs: Calcium and Vitamin D, effects on its metabolite, calcitriol, to ensure the availability of calcium, and plays a key role in calcium homeostasis. Deficiency of these nutrients is harmful to the skeleton, resulting in secondary hyperparathyroidism and, in severe cases, rickets or osteomalacia. Pediatric studies evaluating作者: bonnet 時間: 2025-3-28 01:54
Pediatric Maxillofacial Conditions and Drugs,t can be challenging. Surgical and/or pharmacologic management during skeletal growth affects treatment decisions. In this chapter, we will discuss several maxillofacial bony conditions, their presentation, and management. We will also discuss therapeutic options with associated risks and benefits.作者: calumniate 時間: 2025-3-28 05:00
Newer Adult Bone Drugs,er denosumab, the most recent antiresorptive therapy, and new dosing regimens and formulations of osteoanabolic therapy with parathyroid hormone, parathyroid hormone-related peptide, and their analogs. We also consider new molecules that are currently under development or of interest, including cath作者: coddle 時間: 2025-3-28 06:14 作者: 上下連貫 時間: 2025-3-28 13:20 作者: 行為 時間: 2025-3-28 16:57 作者: PRE 時間: 2025-3-28 18:44 作者: entreat 時間: 2025-3-29 02:59 作者: 煩人 時間: 2025-3-29 03:07
Periodicals, Proceedings, Books, Activities,nagement requires a multidisciplinary approach involving paediatrician, endocrinologist (bone and mineral physician), rehabilitation specialist, orthopaedic surgeon, dentist, physiotherapist and occupational therapist. Bisphosphonate treatment is the mainstay of medical treatment in OI and has been 作者: Debate 時間: 2025-3-29 09:21 作者: staging 時間: 2025-3-29 13:52
